<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title>idarubicin</title><link>http://www.unboundmedicine.com/medline/ebm/research/idarubicin</link><description>Unbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.</description><language>en-us</language><copyright>Unbound Medicine, Inc.</copyright><item><title>Compounds of the anthracycline family of antibiotics elevate human gamma-globin expression both in erythroid cultures and in a transgenic mouse model.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19914848/full_citation/Compounds_of_the_anthracycline_family_of_antibiotics_elevate_human_gamma_globin_expression_both_in_erythroid_cultures_and_in_a_transgenic_mouse_model_</link><description>Spyrou P, Phylactides M, Lederer CW, et al. <br/><span class="title">Compounds of the anthracycline family of antibiotics elevate human gamma-globin expression both in erythroid cultures and in a transgenic mouse model. [JOURNAL ARTICLE]</span><br/><span class="source" title="Blood cells, molecules &amp; diseases">Blood Cells Mol Dis 2009 Nov 13.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19914848/abstract/Compounds_of_the_anthracycline_family_of_antibiotics_elevate_human_gamma_globin_expression_both_in_erythroid_cultures_and_in_a_transgenic_mouse_model_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19914848/full_citation/Compounds_of_the_anthracycline_family_of_antibiotics_elevate_human_gamma_globin_expression_both_in_erythroid_cultures_and_in_a_transgenic_mouse_model_">Full Citation</a></description></item><item><title>Mast cell leukemia with rapidly progressing portal hypertension.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19883434/full_citation/Mast_cell_leukemia_with_rapidly_progressing_portal_hypertension_</link><description>Yoshida M, Nishikawa Y, Yamamoto Y, et al. <br/><span class="title">Mast cell leukemia with rapidly progressing portal hypertension. [JOURNAL ARTICLE]</span><br/><span class="source" title="Pathology international">Pathol Int 2009 Nov; 59(11):817-822.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19883434/abstract/Mast_cell_leukemia_with_rapidly_progressing_portal_hypertension_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19883434/full_citation/Mast_cell_leukemia_with_rapidly_progressing_portal_hypertension_">Full Citation</a></description></item><item><title>Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19860628/full_citation/Mitoxantrone_and_etoposide_in_patients_with_newly_diagnosed_acute_myeloid_leukemia_with_persistent_leukemia_after_a_course_of_therapy_with_cytarabine_and_idarubicin_</link><description>McHayleh W, Sehgal R, Redner RL, et al. <br/><span class="title">Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin. [JOURNAL ARTICLE]</span><br/><span class="source" title="Leukemia &amp; lymphoma">Leuk Lymphoma 2009 Oct 8.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19860628/abstract/Mitoxantrone_and_etoposide_in_patients_with_newly_diagnosed_acute_myeloid_leukemia_with_persistent_leukemia_after_a_course_of_therapy_with_cytarabine_and_idarubicin_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19860628/full_citation/Mitoxantrone_and_etoposide_in_patients_with_newly_diagnosed_acute_myeloid_leukemia_with_persistent_leukemia_after_a_course_of_therapy_with_cytarabine_and_idarubicin_">Full Citation</a></description></item><item><title>Development and validation of a liquid chromatographic method for the simultaneous determination of four anthracyclines and their respective 13-S-dihydro metabolites in plasma and saliva.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19828385/full_citation/Development_and_validation_of_a_liquid_chromatographic_method_for_the_simultaneous_determination_of_four_anthracyclines_and_their_respective_13_S_dihydro_metabolites_in_plasma_and_saliva_</link><description>Maudens KE, Stove CP, Cocquyt VF, et al. <br/><span class="title">Development and validation of a liquid chromatographic method for the simultaneous determination of four anthracyclines and their respective 13-S-dihydro metabolites in plasma and saliva. [JOURNAL ARTICLE]</span><br/><span class="source" title="Journal of chromatography. B, Analytical technologies in the biomedical and life sciences">J Chromatogr B Analyt Technol Biomed Life Sci 2009 Oct 2.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19828385/abstract/Development_and_validation_of_a_liquid_chromatographic_method_for_the_simultaneous_determination_of_four_anthracyclines_and_their_respective_13_S_dihydro_metabolites_in_plasma_and_saliva_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19828385/full_citation/Development_and_validation_of_a_liquid_chromatographic_method_for_the_simultaneous_determination_of_four_anthracyclines_and_their_respective_13_S_dihydro_metabolites_in_plasma_and_saliva_">Full Citation</a> | <a href="http://linkinghub.elsevier.com/retrieve/pii/S1570-0232(09)00689-8">Publisher Full Text</a></description></item><item><title>Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19826132/full_citation/Daunorubicin_versus_mitoxantrone_versus_idarubicin_as_induction_and_consolidation_chemotherapy_for_adults_with_acute_myeloid_leukemia:_the_EORTC_and_GIMEMA_Groups_Study_AML_10_</link><description>Mandelli F, Vignetti M, Suciu S, et al. <br/><span class="title">Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. [Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't]</span><br/><span class="source" title="Journal of clinical oncology : official journal of the American Society of Clinical Oncology">J Clin Oncol 2009 Nov 10; 27(32):5397-403.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19826132/abstract/Daunorubicin_versus_mitoxantrone_versus_idarubicin_as_induction_and_consolidation_chemotherapy_for_adults_with_acute_myeloid_leukemia:_the_EORTC_and_GIMEMA_Groups_Study_AML_10_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19826132/full_citation/Daunorubicin_versus_mitoxantrone_versus_idarubicin_as_induction_and_consolidation_chemotherapy_for_adults_with_acute_myeloid_leukemia:_the_EORTC_and_GIMEMA_Groups_Study_AML_10_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19826132/Daunorubicin_versus_mitoxantrone_versus_idarubicin_as_induction_and_consolidation_chemotherapy_for_adults_with_acute_myeloid_leukemia:_the_EORTC_and_GIMEMA_Groups_Study_AML_10_">Find Related Articles</a> </description></item><item><title>Uptake of anthracyclines in vitro and in vivo in acute myeloid leukemia cells in relation to apoptosis and clinical response.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19820921/full_citation/Uptake_of_anthracyclines_in_vitro_and_in_vivo_in_acute_myeloid_leukemia_cells_in_relation_to_apoptosis_and_clinical_response_</link><description>Bogason A, Bhuiyan H, Masquelier M, et al. <br/><span class="title">Uptake of anthracyclines in vitro and in vivo in acute myeloid leukemia cells in relation to apoptosis and clinical response. [JOURNAL ARTICLE]</span><br/><span class="source" title="European journal of clinical pharmacology">Eur J Clin Pharmacol 2009 Oct 10.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19820921/abstract/Uptake_of_anthracyclines_in_vitro_and_in_vivo_in_acute_myeloid_leukemia_cells_in_relation_to_apoptosis_and_clinical_response_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19820921/full_citation/Uptake_of_anthracyclines_in_vitro_and_in_vivo_in_acute_myeloid_leukemia_cells_in_relation_to_apoptosis_and_clinical_response_">Full Citation</a></description></item><item><title>Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19806665/full_citation/Salvage_therapy_for_acute_myeloid_leukemia_with_fludarabine_cytarabine_and_idarubicin_with_or_without_gemtuzumab_ozogamicin_and_with_concurrent_or_sequential_G_CSF_</link><description>Martin MG, Augustin KM, Uy GL, et al. <br/><span class="title">Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF. [JOURNAL ARTICLE]</span><br/><span class="source" title="American journal of hematology">Am J Hematol 2009 Sep 11.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19806665/abstract/Salvage_therapy_for_acute_myeloid_leukemia_with_fludarabine_cytarabine_and_idarubicin_with_or_without_gemtuzumab_ozogamicin_and_with_concurrent_or_sequential_G_CSF_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19806665/full_citation/Salvage_therapy_for_acute_myeloid_leukemia_with_fludarabine_cytarabine_and_idarubicin_with_or_without_gemtuzumab_ozogamicin_and_with_concurrent_or_sequential_G_CSF_">Full Citation</a></description></item><item><title>High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19800119/full_citation/High_body_mass_index_is_an_independent_predictor_of_differentiation_syndrome_in_patients_with_acute_promyelocytic_leukemia_</link><description>Jeddi R, Ghédira H, Mnif S, et al. <br/><span class="title">High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia. [JOURNAL ARTICLE]</span><br/><span class="source" title="Leukemia research">Leuk Res 2009 Sep 30.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19800119/abstract/High_body_mass_index_is_an_independent_predictor_of_differentiation_syndrome_in_patients_with_acute_promyelocytic_leukemia_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19800119/full_citation/High_body_mass_index_is_an_independent_predictor_of_differentiation_syndrome_in_patients_with_acute_promyelocytic_leukemia_">Full Citation</a></description></item><item><title>Long-term outcomes of de novo acute myeloid leukemia in Thai patients.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19772172/full_citation/Long_term_outcomes_of_de_novo_acute_myeloid_leukemia_in_Thai_patients_</link><description>Niparuck P, Chuncharunee S, Ungkanont A, et al. <br/><span class="title">Long-term outcomes of de novo acute myeloid leukemia in Thai patients. [Journal Article]</span><br/><span class="source" title="Journal of the Medical Association of Thailand = Chotmaihet thangphaet">J Med Assoc Thai 2009 Sep; 92(9):1143-9.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19772172/abstract/Long_term_outcomes_of_de_novo_acute_myeloid_leukemia_in_Thai_patients_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19772172/full_citation/Long_term_outcomes_of_de_novo_acute_myeloid_leukemia_in_Thai_patients_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19772172/Long_term_outcomes_of_de_novo_acute_myeloid_leukemia_in_Thai_patients_">Find Related Articles</a> </description></item><item><title>A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19767767/full_citation/A_comparative_study_of_outcomes_of_idarubicin__and_etoposide_intensified_conditioning_regimens_for_allogeneic_peripheral_blood_stem_cell_transplantation_in_patients_with_high_risk_acute_leukemia_</link><description>Li QB, Li L, You Y, et al. <br/><span class="title">A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia. [JOURNAL ARTICLE]</span><br/><span class="source" title="Acta pharmacologica Sinica">Acta Pharmacol Sin 2009 Sep 21.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19767767/abstract/A_comparative_study_of_outcomes_of_idarubicin__and_etoposide_intensified_conditioning_regimens_for_allogeneic_peripheral_blood_stem_cell_transplantation_in_patients_with_high_risk_acute_leukemia_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19767767/full_citation/A_comparative_study_of_outcomes_of_idarubicin__and_etoposide_intensified_conditioning_regimens_for_allogeneic_peripheral_blood_stem_cell_transplantation_in_patients_with_high_risk_acute_leukemia_">Full Citation</a></description></item></channel></rss>